• Cooperative Research and Development Agreement (CRADA) with USAMRIID, the US' leading BSL-4 biodefense lab
• RECCE® 327 (R327) to be tested against hazardous pathogens in USAMRIID's in vitro infection models
• CRADA is supported and funded by the Defense Threat Reduction Agency

Recce Pharmaceuticals Limited has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), with partnership and funding from the Defense Threat Reduction Agency. USAMRIID will test Recce's synthetic anti-infective RECCE® 327 (R327) against a panel of biodefence pathogens in USAMRIID's established in vitro infection models. Upon successful testing, the next phase of evaluation may progress to small animal model testing. USAMRIID is the United States Army's premier institution and facility for defensive research into countermeasures against biological warfare. The Institute is the only laboratory in the U.S. Department of Defense (DOD) equipped to safely study highly hazardous pathogens requiring maximum containment at Biosafety Level 4. This CRADA is in addition to, and runs parallel to, a recently awarded US$2M burn wound grant by the U.S. Department of Defense Congressionally Directed Medical Research Program (CDMRP) seeking to accelerate the development of R327G and evaluate it as a gel-based treatment to rapidly resolve burn wound infections.

The CRADA with USAMRIID will see R327 tested against hazardous pathogens, which may lead to further small animal model testing. This is in addition to an ongoing US$2M DoD grant for R327G as a burn wound treatment.

The CRADA with USAMRIID and the ongoing DoD grant for R327G further bolster Recce's partnerships with U.S. Government agencies, supporting the development of its synthetic anti-infective pipeline.